Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Diabetologia ; 53(11): 2369-79, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20628728

RESUMO

AIMS/HYPOTHESIS: Prolonged exposure of pancreatic beta cells to excessive levels of glucose and fatty acids, referred to as glucolipotoxicity, is postulated to contribute to impaired glucose homeostasis in patients with type 2 diabetes. However, the relative contribution of defective beta cell function vs diminished beta cell mass under glucolipotoxic conditions in vivo remains a subject of debate. We therefore sought to determine whether glucolipotoxicity in rats is due to impaired beta cell function and/or reduced beta cell mass, and whether older animals are more susceptible to glucolipotoxic condition. METHODS: Wistar rats (2 and 6 months old) received a 72 h infusion of glucose + intravenous fat emulsion or saline control. In vivo insulin secretion and sensitivity were assessed by hyperglycaemic clamps. Ex vivo insulin secretion, insulin biosynthesis and gene expression were measured in isolated islets. Beta cell mass and proliferation were examined by immunohistochemistry. RESULTS: A 72 h infusion of glucose + intravenous fat emulsion in 2-month-old Wistar rats did not affect insulin sensitivity, insulin secretion or beta cell mass. In 6-month-old rats by contrast it led to insulin resistance and reduced insulin secretion in vivo, despite an increase in beta cell mass and proliferation. This was associated with: (1) diminished glucose-stimulated second-phase insulin secretion and proinsulin biosynthesis; (2) lower insulin content; and (3) reduced expression of beta cell genes in isolated islets. CONCLUSIONS/INTERPRETATION: In this in vivo model, glucolipotoxicity is characterised by an age-dependent impairment of glucose-regulated beta cell function despite a marked increase in beta cell mass.


Assuntos
Ácidos Graxos/toxicidade , Glucose/toxicidade , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Animais , Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Imuno-Histoquímica , Técnicas In Vitro , Insulina/metabolismo , Células Secretoras de Insulina/patologia , Masculino , Proinsulina/metabolismo , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa
2.
Diabetologia ; 52(6): 1122-32, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19294363

RESUMO

AIMS/HYPOTHESIS: The Zucker fatty (ZF) rat subjected to 60% pancreatectomy (Px) develops moderate diabetes by 3 weeks. We determined whether a progressive fall in beta cell mass and/or beta cell dysfunction contribute to beta cell failure in this type 2 diabetes model. METHODS: Partial (60%) or sham Px was performed in ZF and Zucker lean (ZL) rats. At 3 weeks post-surgery, beta cell mass and proliferation, proinsulin biosynthesis, pancreatic insulin content, insulin secretion, and islet glucose and lipid metabolism were measured. RESULTS: ZL-Px rats maintained normal glycaemia and glucose-stimulated insulin secretion (GSIS) despite incomplete recovery of beta cell mass possibly due to compensatory enhanced islet glucose metabolism and lipolysis. ZF-Px rats developed moderate hyperglycaemia (14 mmol/l), hypertriacylglycerolaemia and relative hypoinsulinaemia. Despite beta cell mass recovery and normal arginine-induced insulin secretion, GSIS and pancreatic insulin content were profoundly lowered in ZF-Px rats. Proinsulin biosynthesis was not reduced. Compensatory increases in islet glucose metabolism above those observed in ZF-Sham rats were not seen in ZF-Px rats. Triacylglycerol content was not increased in ZF-Px islets, possibly due to lipodetoxification by enhanced lipolysis and fatty acid oxidation. Fatty acid accumulation into monoacylglycerol and diacylglycerol was increased in ZF-Px islets together with a 4.5-fold elevation in stearoyl-CoA desaturase mRNA expression. CONCLUSIONS/INTERPRETATION: Falling beta cell mass, reduced proinsulin biosynthesis and islet steatosis are not implicated in early beta cell failure and glucolipotoxicity in ZF-Px rats. Rather, severe beta cell dysfunction with a specific reduction in GSIS and marked depletion of beta cell insulin stores with altered lipid partitioning underlie beta cell failure in this animal model of type 2 diabetes.


Assuntos
Hiperlipidemias/metabolismo , Hiperlipidemias/patologia , Células Secretoras de Insulina/patologia , Ilhotas Pancreáticas/patologia , Obesidade/metabolismo , Obesidade/patologia , Animais , Peso Corporal , Proliferação de Células , Células Cultivadas , Ácidos Graxos não Esterificados/metabolismo , Hiperlipidemias/fisiopatologia , Imuno-Histoquímica , Insulina/metabolismo , Células Secretoras de Insulina/citologia , Células Secretoras de Insulina/metabolismo , Metabolismo dos Lipídeos/fisiologia , Masculino , Obesidade/fisiopatologia , Pancreatectomia , Proinsulina/metabolismo , Ratos , Ratos Zucker
3.
Diabetes Obes Metab ; 7(4): 360-9, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15955122

RESUMO

Topiramate (TPM) is a novel neurotherapeutic agent. Clinical studies reported that TPM treatment reduced body weight and decreased fasting blood glucose levels in obese patients with or without type 2 diabetes. It is unclear whether the blood glucose-normalizing phenomenon observed during TPM treatment is a primary effect or the consequence of reduced food intake and weight loss. In the present studies, we chronically treated female Zucker diabetic fatty (ZDF) rats (fed with a diabetogenic diet) and db/db mice with TPM (30-300 mg/kg/day) to examine the effect of TPM on hyperglycaemia and its relationship with food intake and body weight gain. Our data showed that TPM treatment markedly reduced blood glucose levels in both ZDF rats and db/db mice without a significant reduction in body weight gain. Pair-fed db/db mice treated with the vehicle alone did not exhibit a significant decrease in blood glucose levels compared with mice fed ad libitum. TPM treatment increased glucose-stimulated insulin release by 2-3-fold during an oral glucose tolerance test in both ZDF rats and db/db mice. We also observed a 1.4-fold increase of pancreatic insulin content and heightened insulin immunostaining in pancreatic beta cells in db/db mice treated with TPM. Our data suggest that the antidiabetic effect of TPM is independent of the changes in body weight gain and food intake. Improved glucose-induced insulin release may, in part, underlie the mechanisms by which TPM ameliorates the hyperglycaemia.


Assuntos
Frutose/análogos & derivados , Hiperglicemia/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina/metabolismo , Abdome , Tecido Adiposo/efeitos dos fármacos , Animais , Glicemia/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Frutose/uso terapêutico , Teste de Tolerância a Glucose/métodos , Hiperglicemia/metabolismo , Hiperglicemia/patologia , Ilhotas Pancreáticas/patologia , Camundongos , Camundongos Endogâmicos C57BL , Fármacos Neuroprotetores/uso terapêutico , Pâncreas/metabolismo , Ratos , Ratos Zucker , Topiramato , Triglicerídeos/sangue , Aumento de Peso/efeitos dos fármacos
4.
Metabolism ; 50(11): 1377-84, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11699060

RESUMO

Sympatholytic dopamine agonist treatment utilizing bromocriptine and SKF38393 (BC/SKF) significantly lowers basal plasma insulin levels and normalizes basal and glucose-induced insulin secretion of the pancreatic beta cell in ob/ob mice. While BC/SKF has no significant effect on pancreatic islet cells directly, drug action is mediated via alterations in the hypothalamic-neuroendocrine axis, which drives metabolic changes in peripheral tissues leading to a marked reduction in hyperglycemia and hyperlipidemia and corrects autonomic control of islet function. To elucidate the nature of the functional response of islets to systemic BC/SKF treatment in ob/ob mice, we investigated the relative changes in the levels of functionally important beta-cell proteins in situ, as well as differences in the beta-cell turnover rate, following a 2-week drug treatment. Isolated islets from treated mice exhibit a 3.5-fold increase in insulin content (P <.01) that correlated with a 51% reduction in basal plasma insulin levels (P <.01) compared with vehicle-treated controls. Using quantitative immunofluorescence microscopy on pancreatic tissue sections, insulin and GLUT2 immunoreactivity of islet beta cells of BC/SKF-treated mice were significantly increased (approximately 2.3-fold and approximately 4.4-fold, respectively; P <.002) to the levels observed in islets of their lean littermates. Glucokinase (GK) immunoreactivity was greatly (75%) reduced in beta cells from ob/ob versus lean mice (P <.0001). A modest increase in GK immunoreactivity in beta cells of drug-treated mice was observed (approximately 1.6-fold; P <.05). Isolated islets from BC/SKF-treated mice exhibit a 42% reduction in DNA content compared with vehicle-treated controls (P <.01) to levels observed in lean mice, but without notable differences in islet size. In situ assays for mitosis and apoptosis, using 5-bromodeoxyuridine (BrdU) and terminal deoxyribotransferase (TdT)-UTP nick end labeling (TUNEL) staining techniques, respectively, were performed in pancreas of these mice to determine if beta cells show a reduction in hyperplasia following BC/SKF treatment. Accordingly, a pronounced decrease in replicating, BrdU-positive beta cells in the drug-treated mice compared with the control group was observed, but without differences in their TUNEL-staining patterns. Collectively, these data suggest that systemic sympatholytic dopaminergic therapy that attenuates hyperglycemia and hyperlipidemia improves islet function in ob/ob mice by improving aberrations in the beta cell's glucose-sensing apparatus, enhancing insulin storage and/or retention, and stabilizing hyperplasia, thus reducing basal insulin levels.


Assuntos
Agonistas de Dopamina/farmacologia , Glucoquinase/metabolismo , Insulina/metabolismo , Ilhotas Pancreáticas/efeitos dos fármacos , Proteínas de Transporte de Monossacarídeos/metabolismo , Simpatolíticos/farmacologia , Animais , Apoptose/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , DNA/metabolismo , Feminino , Glucagon/metabolismo , Transportador de Glucose Tipo 2 , Hiperplasia/patologia , Hiperplasia/prevenção & controle , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Ilhotas Pancreáticas/metabolismo , Ilhotas Pancreáticas/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Obesos , Somatostatina/metabolismo
5.
Diabetologia ; 44(11): 2056-65, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11719838

RESUMO

AIMS/HYPOTHESIS: Early compensatory mechanisms of regeneration following partial pancreatectomy involve ductal proliferation and, subsequently, differentiation into acinar and endocrine cell types, although it is not clear how these processes are regulated. We investigated the expression and roles of insulin receptor substrate-2 (IRS-2) and protein kinase B/Akt (Akt) in pancreatic regeneration that starts with the common duct epithelium using a non-diabetic model of beta cell adaptation and mass expansion, 60 %-pancreatectomy rats. METHODS: We used confocal immunofluorescence microscopy to study IRS-2 and Akt expression and activation in pancreatic common ducts at intervals after surgery. These proteins were studied in relation to proliferation markers and insulin immunostaining. RESULTS: In pancreatectomized rats, a short-term increase in proliferation was observed in the common duct epithelial lining ( approximately 4-fold) compared with sham-operated control rats which correlated with about a 1.8-fold increase in IRS-2 immunoreactivity 2 days after surgery. Interspersed with proliferating cells of the common duct, evaginations were rare single and clustered insulin immunopositive cells which expressed high levels of IRS-2 immunoreactivity. Epithelium of duct evaginations from 2-day post-Px rats exhibited striking phospho-Akt staining ( approximately 3.5-fold above control rats) without any detectable changes in total Akt staining. CONCLUSION/INTERPRETATION: Our data suggest that IRS-2 plays an important role in pancreatic regeneration and growth by mediating duct proliferation and by maintaining the differentiated beta cell. The restricted staining pattern of phospho-Akt to cells of the common duct evaginations suggests that it has a role in regulating post-mitotic events related to cell-specific gene expression or survival or both.


Assuntos
Regulação da Expressão Gênica , Pancreatectomia , Ductos Pancreáticos/fisiologia , Fosfoproteínas/genética , Proteínas Serina-Treonina Quinases , Proteínas Proto-Oncogênicas/genética , Regeneração , Animais , Células CHO , Divisão Celular , Cricetinae , Células Epiteliais/citologia , Células Epiteliais/fisiologia , Imunofluorescência , Proteínas Substratos do Receptor de Insulina , Peptídeos e Proteínas de Sinalização Intracelular , Cinética , Masculino , Microscopia Confocal , Ductos Pancreáticos/citologia , Proteínas Proto-Oncogênicas c-akt , Ratos , Ratos Sprague-Dawley , Receptor de Insulina/genética , Fatores de Tempo , Transfecção
6.
Diabetes ; 50(3): 622-9, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11246883

RESUMO

Transgenic mice that overexpress the entire glucokinase (GK) gene locus have been previously shown to be mildly hypoglycemic and to have improved tolerance to glucose. To determine whether increased GK might also prevent or diminish diabetes in diet-induced obese animals, we examined the effect of feeding these mice a high-fat high-simple carbohydrate low-fiber diet (HF diet) for 30 weeks. In response to this diet, both normal and transgenic mice became obese and had similar BMIs (5.3 +/- 0.1 and 5.0 +/- 0.1 kg/m2 in transgenic and non-transgenic mice, respectively). The blood glucose concentration of the control mice increased linearly with time and reached 17.0 +/- 1.3 mmol/l at the 30th week. In contrast, the blood glucose of GK transgenic mice rose to only 9.7 +/- 1.2 mmol/l at the 15th week, after which it returned to 7.6 +/- 1.0 mmol/l by the 30th week. The plasma insulin concentration was also lower in the GK transgenic animals (232 +/- 79 pmol/l) than in the controls (595 +/- 77 pmol/l), but there was no difference in plasma glucagon concentrations. Together, these data indicate that increased GK levels dramatically lessen the development of both hyperglycemia and hyperinsulinemia associated with the feeding of an HF diet.


Assuntos
Mapeamento Cromossômico , Diabetes Mellitus Tipo 2/etiologia , Diabetes Mellitus Tipo 2/genética , Predisposição Genética para Doença , Glucoquinase/genética , Obesidade/complicações , Transgenes/fisiologia , Animais , Glicemia/análise , Gorduras na Dieta/administração & dosagem , Glucagon/sangue , Glucoquinase/metabolismo , Insulina/sangue , Fígado/enzimologia , Camundongos , Camundongos Transgênicos/genética , Obesidade/sangue , Obesidade/etiologia , RNA Mensageiro/metabolismo , Valores de Referência
7.
Int J Exp Diabetes Res ; 2(3): 173-86, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-12369705

RESUMO

Hepatic glucokinase (GK) is acutely regulated by binding to its nuclear-anchored regulatory protein (GKRP). Although GK release by GKRP is tightly coupled to the rate of glycogen synthesis, the nature of this association is obscure. To gain insight into this coupling mechanism under physiological stimulating conditions in primary rat hepatocytes, we analyzed the subcellular distribution of GK and GKRP with immunofluorescence, and glycogen deposition with glycogen cytochemical fluorescence, using confocal microscopy and quantitative image analysis. Following stimulation, a fraction of the GK signal translocated from the nucleus to the cytoplasm. The reduction in the nuclear to cytoplasmic ratio of GK, an index of nuclear export, correlated with a >50% increase in glycogen cytochemical fluorescence over a 60 min stimulation period. Furthermore, glycogen accumulation was initially deposited in a peripheral pattern in hepatocytes similar to that of GK. These data suggest that a compartmentalization exists of both active GK and the initial sites of glycogen deposition at the hepatocyte surface.


Assuntos
Proteínas de Transporte , Núcleo Celular/enzimologia , Glucoquinase/metabolismo , Glicogênio Hepático/biossíntese , Fígado/enzimologia , Transporte Ativo do Núcleo Celular , Animais , Células Cultivadas , Peptídeos e Proteínas de Sinalização Intracelular , Cinética , Perfusão , Proteínas/metabolismo , Ratos , Ratos Sprague-Dawley
8.
Am J Physiol Regul Integr Comp Physiol ; 278(2): R435-44, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10666145

RESUMO

Increases in ventromedial hypothalamic (VMH) norepinephrine (NE) levels and/or activities have been observed in a variety of animal models of the obese insulin-resistant condition. This study examined the metabolic effects of chronic NE infusion (25 nmol/h) into the unilateral VMH of normal rats. Within 4 days, VMH NE infusion significantly increased plasma insulin (140%), glucagon (45%), leptin (300%), triglyceride (100%), abdominal fat pad weight (50%), and white adipocyte lipogenic (100%) and lipolytic (100%) activities relative to vehicle-infused rats. Furthermore, isolated islet insulin secretory response to glucose (15 mM) within 4 days of such treatment was increased over twofold (P < 0.05). Among treated animals, fat stores continued to increase over time and plateaued at approximately 2 wk (3-fold increase), remaining elevated to the end of the study (5 wk). By week 4 of treatment, NE infusion induced glucose intolerance as evidenced by a 32% increase in plasma glucose total area under the glucose tolerance test curve (P < 0.01). Whole body fat oxidation rate measured after 5 wk of infusion was significantly increased among treated animals as evidenced by a reduced respiratory quotient (0.87 +/- 0.01) relative to controls (0. 90 +/- 0.01). VMH NE infusion induced hyperphagia (30%) only during the first week and did not affect body weight over the 5-wk period. Increases in VMH NE activity that are common among obese insulin-resistant animal models can cause the development of this obese glucose-intolerant (metabolic) syndrome.


Assuntos
Intolerância à Glucose , Norepinefrina/administração & dosagem , Obesidade/fisiopatologia , Núcleo Hipotalâmico Ventromedial/fisiologia , Tecido Adiposo/patologia , Animais , Metabolismo dos Carboidratos , Glândulas Endócrinas/fisiopatologia , Feminino , Hormônios/sangue , Injeções , Isoproterenol/farmacologia , Leptina/sangue , Metabolismo dos Lipídeos , Lipólise/efeitos dos fármacos , Lipólise/fisiologia , Norepinefrina/farmacologia , Obesidade/patologia , Ratos , Ratos Sprague-Dawley , Valores de Referência , Síndrome , Fatores de Tempo
9.
Mol Cell Neurosci ; 14(2): 99-120, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10532808

RESUMO

alpha-Calcitonin gene-related peptide (alphaCGRP) is a pleiotropic peptide neuromodulator that is widely expressed throughout the Central and peripheral nervous systems. CGRP has been implicated in a variety of physiological processes including peripheral vasodilation, cardiac acceleration nicotinic acetylcholine receptor (AChR) synthesis and function, testicular descent, nociception, carbohydrate metabolism, gastrointestinal motility, neurogenic inflammation, and gastric acid secretion. To provide a better understanding of the physiological role(s) mediated by this peptide neurotransmitter, we have generated alphaCGRP-null mice by targeted modification in embryonic stem cells. Mice lacking alpha CGRP expression demonstrate no obvious phenotypic differences from their wild-type littermates. Detailed analysis of systemic cardiovascular function revealed no differences between control and mutant mice regarding heart rate and blood pressure under basal or exercise-induced conditions and subsequent to pharmacological manipulation. Characterization of neuromuscular junction in morphology including nicotinic receptor localization, terminal sprouting in response to denervation, developmental regulation of AChR subunit expression, and synapse elimination also revealed no differences in alphaCGRP-deficient animals. These results suggest that alphaCGRP is not required for the systemic regulation of cardiovascular hemodynamics or development of the neuromuscular junction.


Assuntos
Aorta/fisiologia , Pressão Sanguínea/fisiologia , Peptídeo Relacionado com Gene de Calcitonina/fisiologia , Frequência Cardíaca/fisiologia , Coração/fisiologia , Junção Neuromuscular/fisiologia , Receptores Nicotínicos/genética , Envelhecimento/fisiologia , Sequência de Aminoácidos , Animais , Aorta/crescimento & desenvolvimento , Aorta/inervação , Sequência de Bases , Peptídeo Relacionado com Gene de Calcitonina/deficiência , Peptídeo Relacionado com Gene de Calcitonina/genética , Coração/crescimento & desenvolvimento , Coração/inervação , Camundongos , Camundongos Knockout , Dados de Sequência Molecular , Fenótipo , Esforço Físico , Mapeamento por Restrição , Células-Tronco/fisiologia
10.
J Biol Chem ; 274(1): 305-15, 1999 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-9867845

RESUMO

Glucokinase (GK) gene mutations cause diabetes mellitus in both humans and mouse models, but the pathophysiological basis is only partially defined. We have used cre-loxP technology in combination with gene targeting to perform global, beta cell-, and hepatocyte-specific gene knock-outs of this enzyme in mice. Gene targeting was used to create a triple-loxed gk allele, which was converted by partial or total Cre-mediated recombination to a conditional allele lacking neomycin resistance, or to a null allele, respectively. beta cell- and hepatocyte-specific expression of Cre was achieved using transgenes that contain either insulin or albumin promoter/enhancer sequences. By intercrossing the transgenic mice that express Cre in a cell-specific manner with mice containing a conditional gk allele, we obtained animals with either a beta cell or hepatocyte-specific knock-out of GK. Animals either globally deficient in GK, or lacking GK just in beta cells, die within a few days of birth from severe diabetes. Mice that are heterozygous null for GK, either globally or just in the beta cell, survive but are moderately hyperglycemic. Mice that lack GK only in the liver are only mildly hyperglycemic but display pronounced defects in both glycogen synthesis and glucose turnover rates during a hyperglycemic clamp. Interestingly, hepatic GK knock-out mice also have impaired insulin secretion in response to glucose. These studies indicate that deficiencies in both beta cell and hepatic GK contribute to the hyperglycemia of MODY-2.


Assuntos
Glucoquinase/metabolismo , Glucose/metabolismo , Homeostase , Integrases/genética , Ilhotas Pancreáticas/metabolismo , Fígado/metabolismo , Proteínas Virais , Albuminas/genética , Alelos , Animais , Sequência de Bases , Primers do DNA , Deleção de Genes , Glucoquinase/genética , Insulina/genética , Ilhotas Pancreáticas/enzimologia , Fígado/enzimologia , Camundongos , Camundongos Knockout , Transgenes
11.
Cell Mol Life Sci ; 54(7): 703-11, 1998 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9711236

RESUMO

Dysfunction of pancreatic islets plays a crucial role in the etiology of type II diabetes. Chronic hyperglycaemia or hyperlipidaemia may impair islet function. Previous studies by our laboratory have demonstrated that dopaminergic agonists ameliorated hyperglycaemia and hyperlipidaemia in obese and diabetic rodents. In the present study, we investigated the effect of a treatment with the dopamine D2/D1 receptor agonists (bromocriptine/SKF38393, BC/SKF) on islet dysfunction in db/db mice. Our results show that a 2-week BC/SKF treatment markedly reduced hyperglycaemia and hyperlipidaemia, and significantly improved islet dysfunction demonstrated by an increase of secretagogue-stimulated insulin release from islets of db/db mice to levels observed in islets from lean mice. There was also a fourfold increase of insulin content in the pancreas of BC/SKF-treated db/db mice compared with that in untreated controls. The effect of BC/SKF on islet function cannot be mimicked in pair-fed animals. BC/SKF had no direct stimulatory effect on islet insulin secretion, suggesting BC/SKF treatment improved islet function via an indirect mechanism. This treatment markedly improved the abnormally elevated daily levels of corticosterone, blood glucose and plasma lipids, supporting the view that BC/SKF may affect the neuroendocrine system that in turn regulates peripheral metabolism and thereby improves islet function.


Assuntos
Bromocriptina/farmacologia , Ilhotas Pancreáticas/efeitos dos fármacos , Animais , Glicemia/efeitos dos fármacos , Corticosterona/sangue , Diabetes Mellitus Tipo 2 , Modelos Animais de Doenças , Agonistas de Dopamina/farmacologia , Imunofluorescência , Imuno-Histoquímica , Insulina/sangue , Ilhotas Pancreáticas/patologia , Lipídeos/sangue , Camundongos , Camundongos Obesos , Pâncreas/efeitos dos fármacos , Pâncreas/patologia
12.
Proc Natl Acad Sci U S A ; 95(15): 8654-9, 1998 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-9671733

RESUMO

Transgenic mice containing an upstream glucokinase (betaGK) promoter- simian virus 40 T antigen (Tag) fusion gene develop neuroendocrine tumors primarily in the pancreas, gut, and pituitary. Pancreatic tumors from a line with delayed tumorigenesis were of two different types: insulinomas and noninsulinomas. The noninsulinomas are often periductal in location, express none of the four major islet peptide hormones, Glut-2, Pdx1, tyrosine hydroxylase, Pax4, Pax6, or Nkx6.1, but do express glucokinase, Sur1, Isl1, Hnf3beta, Hnf6, Beta2/NeuroD, and Nkx2.2. Cells from two different noninsulinoma tumors, when adapted to culture, began to express either insulin, glucagon, or somatostatin. Given the partial gene expression repertoire of the noninsulinoma tumors, their apparent periductal origin, and the ability of these cells to partially cytodifferentiate in culture, we suggest that these tumors are derived from islet progenitor cells. Thus, betaGK-Tag transgenic mice provide a new model system for studying the events that occur during both islet cell neogenesis and normal embryonic development.


Assuntos
Insulina/metabolismo , Ilhotas Pancreáticas/patologia , Neoplasias Pancreáticas/patologia , Animais , Genes Reporter , Glucoquinase/genética , Proteína Homeobox Nkx-2.2 , Imuno-Histoquímica , Ilhotas Pancreáticas/enzimologia , Ilhotas Pancreáticas/metabolismo , Camundongos , Camundongos Transgênicos , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo
13.
J Biol Chem ; 272(36): 22564-9, 1997 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-9278410

RESUMO

Transgenic mice containing one or more extra copies of the entire glucokinase (GK) gene locus were generated and characterized. The GK transgene, an 83-kilobase pair mouse genomic DNA fragment containing both promoter regions, was expressed and regulated in a cell-specific manner, and rescued GK null lethality when crossed into mice bearing a targeted mutation of the endogenous GK gene. Livers from the transgenic mice had elevated GK mRNA, protein, and activity levels, compared with controls, and the transgene was regulated in liver by dietary manipulations. The amount of GK immunoreactivity in hepatocyte nuclei, where GK binds to the GK regulatory protein, was also increased. Pancreatic islets displayed increased GK immunoreactivity and NAD(P)H responses to glucose, but only when isolated and cultured in 20 mM glucose, as a result of the hypoglycemic phenotype of these mice (Niswender, K. D., Shiota, M., Postic, C., Cherrington, A. D., and Magnuson, M. A. (1997) J. Biol. Chem. 272, 22604-22609). Together, these results indicate that the region of the gene from -55 to +28 kilobase pairs (relative to the liver GK transcription start site) contains all the regulatory sequences necessary for expression of both GK isoforms, thereby placing an upper limit on the size of the GK gene locus.


Assuntos
Regulação Enzimológica da Expressão Gênica , Glucoquinase/genética , Transgenes , Animais , Ilhotas Pancreáticas/enzimologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Camundongos Transgênicos , Frações Subcelulares/enzimologia
14.
Development ; 124(7): 1263-74, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9118797

RESUMO

The mouse Mf3 gene, also known as Fkh5 and HFH-e5.1, encodes a winged helix/forkhead transcription factor. In the early embryo, transcripts for Mf3 are restricted to the presomitic mesoderm and anterior neurectoderm and mesoderm. By 9.5 days post coitum, expression in the nervous system is predominantly in the diencephalon, midbrain and neural tube. After midgestation, the highest level of mRNA is in the mammillary bodies, the posterior-most part of the hypothalamus. Mice homozygous for a deletion of the mf3 locus on a [129 x Black Swiss] background display variable phenotypes consistent with a requirement for the gene at several stages of embryonic and postnatal development. Approximately six percent of the mf3-/- embryos show an open neural tube in the diencephalon and midbrain region, and another five percent show a severe reduction of the posterior body axis; both these classes of affected embryos die in utero. Surviving homozygotes have an apparently normal phenotype at birth. Postnatally, however, mf3-/- pups are severely growth retarded and approximately one third die before weaning. This growth defect is not a direct result of lack of circulating growth hormone or thyrotropin. Mice that survive to weaning are healthy, but they show an abnormal clasping of the hindfeet when suspended by the tail. Although much smaller than normal, the mice are fertile. However, mf3-/- females cannot eject their milk supply to feed their pups. This nursing defect can be corrected with interperitoneal injections of oxytocin. These results provide evidence that Mf3 is required for normal hypothalamus development and suggest that Mf3 may play a role in postnatal growth and lactation.


Assuntos
Padronização Corporal/genética , Encéfalo/embriologia , Encéfalo/crescimento & desenvolvimento , Proteínas de Ligação a DNA/genética , Ejeção Láctea/fisiologia , Fatores de Transcrição/genética , Animais , Comportamento Animal/fisiologia , Quimera , Cruzamentos Genéticos , Diencéfalo/embriologia , Diencéfalo/crescimento & desenvolvimento , Feminino , Fatores de Transcrição Forkhead , Heterozigoto , Membro Posterior/fisiologia , Homozigoto , Hipotálamo/anatomia & histologia , Imuno-Histoquímica , Masculino , Glândulas Mamárias Animais/anormalidades , Mesencéfalo/embriologia , Mesencéfalo/crescimento & desenvolvimento , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Camundongos Mutantes , Fenótipo , Hipófise/fisiologia , Radioimunoensaio , Reflexo/genética
16.
Proc Natl Acad Sci U S A ; 94(2): 657-62, 1997 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-9012840

RESUMO

Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer, possibly via cyclooxygenase (COX) inhibition. The growth factor-inducible COX-2, which is overexpressed in neoplastic colonic tissue, is an attractive target to mediate this effect. Herein we have exploited the ability of a human colon cancer cell line, HCA-7 Colony 29, to polarize when cultured on Transwell (Costar) filters to study COX-2 production and the vectorial release of prostaglandins (PGs). Administration of type alpha transforming growth factor to the basolateral compartment, in which the epidermal growth factor receptor (EGFR) resides, results in a marked induction of COX-2 immunoreactivity at the base of the cells and the unexpected appearance of COX-2 in the nucleus. The increase in COX-2 protein is associated with a dose- and time-dependent increase in PG levels in the basolateral, but not apical, medium. Amphiregulin is the most abundantly expressed EGFR ligand in these cells, and the protein is present at the basolateral surface. EGFR blockade reduces baseline COX-2 immunoreactivity, PG levels, and mitogenesis in a concentration-dependent manner. Two specific COX-2 inhibitors, SC-58125 and NS 398, also, in a dose-dependent manner, attenuate baseline and type alpha transforming growth factor-stimulated mitogenesis, although PG levels are decreased > 90% at all concentrations of inhibitor tested. These findings show that activation of the EGFR stimulates COX-2 production and its translocation to the nucleus, vectorial release of PGs, and mitogenesis in polarized HCA-7 Colony 29 cells.


Assuntos
Receptores ErbB/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular , Isoenzimas/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismo , Prostaglandinas/metabolismo , Anfirregulina , Compartimento Celular , Núcleo Celular/metabolismo , Polaridade Celular , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/farmacologia , Família de Proteínas EGF , Glicoproteínas/metabolismo , Substâncias de Crescimento/metabolismo , Humanos , Proteínas de Membrana , Mitose , Nitrobenzenos/farmacologia , Pirazóis/farmacologia , RNA Neoplásico/metabolismo , Sulfonamidas/farmacologia , Sulindaco/análogos & derivados , Sulindaco/farmacologia , Fator de Crescimento Transformador alfa/farmacologia , Células Tumorais Cultivadas
17.
Development ; 122(3): 983-95, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8631275

RESUMO

It has been proposed that the Xenopus homeobox gene, XlHbox8, is involved in endodermal differentiation during pancreatic and duodenal development (Wright, C.V.E., Schnegelsberg, P. and De Robertis, E.M. (1988). Development 105, 787-794). To test this hypothesis directly, gene targeting was used to make two different null mutations in the mouse XlHbox8 homolog, pdx-1. In the first, the second pdx-1 exon, including the homeobox, was replaced by a neomycin resistance cassette. In the second, a lacZ reporter was fused in-frame with the N terminus of PDX-1, replacing most of the homeodomain. Neonatal pdx-1 -/- mice are apancreatic, in confirmation of previous reports (Jonsson, J., Carlsson, L., Edlund, T. and Edlund, H. (1994). Nature 371, 606-609). However, the pancreatic buds do form in homozygous mutants, and the dorsal bud undergoes limited proliferation and outgrowth to form a small, irregularly branched, ductular tree. This outgrowth does not contain insulin or amylase-positive cells, but glucagon-expressing cells are found. The rostral duodenum shows a local absence of the normal columnar epithelial lining, villi, and Brunner's glands, which are replaced by a GLUT2-positive cuboidal epithelium resembling the bile duct lining. Just distal of the abnormal epithelium, the numbers of enteroendocrine cells in the villi are greatly reduced. The PDX-1/beta-galactosidase fusion allele is expressed in pancreatic and duodenal cells in the absence of functional PDX-1, with expression continuing into perinatal stages with similar boundaries and expression levels. These results offer additional insight into the role of pdx-1 in the determination and differentiation of the posterior foregut, particularly regarding the proliferation and differentiation of the pancreatic progenitors.


Assuntos
Duodeno/embriologia , Genes Homeobox , Proteínas de Homeodomínio , Pâncreas/embriologia , Transativadores/fisiologia , Animais , Colecistocinina/metabolismo , Endoderma , Regulação da Expressão Gênica no Desenvolvimento , Transportador de Glucose Tipo 2 , Heterozigoto , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Proteínas de Transporte de Monossacarídeos/genética , RNA Mensageiro/genética , Secretina/metabolismo , Serotonina/metabolismo
18.
Nat Genet ; 12(3): 303-8, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8589722

RESUMO

Germline mutations in BRCA1 are responsible for most cases of inherited breast and ovarian cancer. However, the function of the BRCA1 protein has remained elusive. We now show that BRCA1 encodes a 190-kD protein with sequence homology and biochemical analogy to the granin protein family. Interestingly, BRCA2 also includes a motif similar to the granin consensus at the C terminus of the protein. Both BRCA1 and the granins localize to secretory vesicles, are secreted by a regulated pathway, are post-translationally glycosylated and are responsive to hormones. As a regulated secretory protein, BRCA1 appears to function by a mechanism not previously described for tumour suppressor gene products.


Assuntos
Neoplasias da Mama/genética , Proteínas de Neoplasias/metabolismo , Neoplasias Ovarianas/genética , Fatores de Transcrição/metabolismo , Sequência de Aminoácidos , Animais , Anticorpos/imunologia , Proteína BRCA1 , Proteína BRCA2 , Mama/metabolismo , Epitélio/metabolismo , Feminino , Genes Supressores de Tumor , Humanos , Proteínas de Membrana/química , Dados de Sequência Molecular , Peso Molecular , Proteínas de Neoplasias/química , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/imunologia , Proteínas/química , Coelhos , Homologia de Sequência de Aminoácidos , Fatores de Transcrição/química , Fatores de Transcrição/genética , Fatores de Transcrição/imunologia , Células Tumorais Cultivadas
19.
J Biol Chem ; 271(7): 3647-51, 1996 Feb 16.
Artigo em Inglês | MEDLINE | ID: mdl-8631975

RESUMO

Studies of dispersed beta cells have been used to infer their behavior in the intact pancreatic islet. When dispersed, beta cells exhibit multiple metabolic glucose-response populations with different insulin secretion properties. This has led to a model for glucose-dependent insulin secretion from the islet based on a step-wise recruitment of individual beta cells. However, previously reported synchronous and uniform Ca2+ activity and electrical responses indicate that beta cell behavior within intact islets is more uniform. Therefore, uncertainty remains whether beta cell metabolic heterogeneity is functionally important in intact islets. We have used two-photon excitation microscopy to measure and compare the glucose-induced NAD(P)H autofluorescence response in dispersed beta cells and within intact islets. Over 90% of beta cells in intact islets responded to glucose with significantly elevated NAD(P)H levels, compared with less than 70% of dispersed beta cells. In addition, all responding beta cells within intact islets exhibited a sigmoidal glucose dose response behavior with inflection points of approximately 8 mm glucose. These results suggest that beta cell heterogeneity may be functionally less important in the intact islet than has been predicted from studies of dispersed beta cells and support the role of glucokinase as the rate-limiting enzyme in the beta cell glucose response.


Assuntos
Glucose/metabolismo , Ilhotas Pancreáticas/metabolismo , NADP/metabolismo , NAD/metabolismo , Animais , Células Cultivadas , Imunofluorescência , Glucoquinase/metabolismo , Ilhotas Pancreáticas/citologia , Cinética , Microscopia Confocal/métodos , NAD/análise , NADP/análise , Ratos , Frações Subcelulares/metabolismo , Frações Subcelulares/ultraestrutura
20.
Mol Cell Biol ; 14(10): 6773-88, 1994 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7935395

RESUMO

We report the fortuitous isolation of cDNA clones encoding a novel zinc finger DNA-binding protein termed BZP. The protein encoded is 114 kDa and contains eight zinc finger motifs, seven of which are present in two clusters at opposite ends of the molecule. Both finger clusters bound to the 9-bp sequence AAAGGTGCA with apparent Kds of approximately 2.5 nM. Two of the finger motifs within the amino- and carboxy-terminal finger clusters share 63% amino acid identity. BZP inhibited transcription of the herpes simplex virus thymidine kinase promoter when copies of the 9-bp target motif were linked in cis, suggesting that it functions as a transcriptional repressor. BZP mRNA and immunoreactivity were detected in several established cell lines but were most abundant in hamster insulinoma (HIT) cells, the parental source of the cDNAs. In mouse tissues, BZP mRNA and immunoreactivity were identified in cells of the endocrine pancreas, anterior pituitary, and central nervous system. Interestingly, in HIT cells proliferating in culture, BZP immunoreactivity was predominately nuclear in location, whereas it was usually located in the cytoplasm in most neural and neuroendocrine tissues. Serum deprivation of HIT cells caused BZP immunoreactivity to become predominantly cytoplasmic in location and attenuated its inhibitory effect on transcription, thereby suggesting that the both the subcellular location and the function of this protein are modulated by factors in serum.


Assuntos
Proteínas de Ligação a DNA/genética , Proteínas Repressoras , Fatores de Transcrição , Transcrição Gênica , Dedos de Zinco , Sequência de Aminoácidos , Animais , Sequência de Bases , Compartimento Celular , Sistema Nervoso Central/metabolismo , Clonagem Molecular , Meios de Cultura Livres de Soro , DNA Complementar/genética , Proteínas de Ligação a DNA/isolamento & purificação , Proteínas de Ligação a DNA/metabolismo , Regulação da Expressão Gênica , Ilhotas Pancreáticas/metabolismo , Camundongos , Dados de Sequência Molecular , Fragmentos de Peptídeos/metabolismo , Adeno-Hipófise/metabolismo , RNA Mensageiro/análise , Proteínas Recombinantes/metabolismo , Mapeamento por Restrição , Análise de Sequência de DNA , Homologia de Sequência de Aminoácidos , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA